Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany

NCT03518060 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03518060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03518060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Lead sponsor
ViiV Healthcare
Phase
Observational
Overall status
Completed
Start date
June 25, 2018
Completion date
May 14, 2023
Enrollment
209 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections